Clinical trial NCT01525017: A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
Official title: A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Renal Cell Carcinoma
Lead sponsor: Mendus
Sponsor class: INDUSTRY
First posted: 2012-02-02
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell carcinoma will get Combig-DC vaccinations at two occasions in a two weeks period (day 1 and day 14). After another two weeks the kidney will be eliminated. Adverse events will be registered, as well as changes in vital signs(heart rate, blood pressure and body temperature) and lab parameters. Immunologic response will be evaluated by measuring immunologic markers in blood and tumour tissue, and measuring the size of the metastases three months after nephrectomy.


Eligibility criteria: Inclusion Criteria:

1. Be informed of the nature of the study and have provided written informed consent
2. At least 18 years of age.
3. Diagnosis of renal cell carcinoma with at least one distant metastasis, and/or one distant lymph node metastasis.
4. Tumor size (renal cell carcinoma; primary tumor) at least 4.0 cm in longest diameter as measured by CT. Distant metastasis at least 1 cm diameter as measured by CT or a distant lymph node metastasis at least 2,5 cm diameter as measured by CT. Clinical stage 'T1b or more; NX; M1'
5. Adequate hematological parameters, i.e:

   B-Leukocyte count ≥ 4.5 x 109/L B-Platelet count ≥ 150 x109/L B-Haemoglobin ≥ 100 g/L
6. Women of Childbearing Potential (WOCBP) should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.

Exclusion Criteria:

1. Performance status \> ECOG 2 after optimization of analgesics
2. Adequate coagulation parameters, i.e: P-Prothrombin complex (PK), P-APT time
3. Ongoing treatment with systemic corticosteroids (inhaled, intranasal and local steroids accepted) within 28 days before first vaccination.
4. Previously known or ongoing active autoimmune disease which requires treatment with systemic immunosuppressive agents. E.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.
5. Patients with previous or ongoing skin malignancy (basal-cell carcinoma, squamous cell carcinoma, melanoma), other hematological or solid malignancy or blood dysfunctions.
6. Ongoing infection that requires treatment with antibiotics.
7. Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
8. Known malignancy in CNS.
9. Active or latent virus disease (HIV, HBV and HCV).
10. Ongoing pregnancy or lactation. Females needs to have negative pregnancy test at screening visit.
11. Life expectancy less than 3 months.
12. Concomitant exposure to other investigational products.
13. Any reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.

Primary outcomes:
measure: Registration of adverse events as a measure of safety and tolerability
timeFrame: 1 year 3 months (Feb 2012-May 2013)
measure: Changes in vital signs from baseline (heart rate, blood pressure, body temperature) as a measure of safety and tolerability
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
measure: Changes in lab parameters from baseline as a measure of safety and tolerability
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
Secondary outcomes:
measure: Immunologic response in blood (immunologic panel) measured with ELISPOT.
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
measure: Examination of immunohistology parameters (macrophage marker, CD3, CD4, CD8, CD56) of the renal tumor post nephrectomy.
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
measure: CT-evaluation of the size of the metastasis(-es) 3 months post nephrectomy
timeFrame: 1 year 3 months (Feb 2012 - March 2013)
measure: CT evaluation to evaluate number of metastases 3 months post nephrectomy.
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
measure: Changes in body weight 3 months post nephrectomy vs. baseline.
timeFrame: 1 year 3 months (Feb 2012 - May 2013)
measure: Changes in WHO-ECOG 3 months post nephrectomy vs. baseline.
timeFrame: 1 year 3 months (Feb 2012 - may 2013)
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Dept of Oncology, University Hospital
Study officials:
affiliation: Dept of Oncology , Uppsala University Hospital
name: Anna Laurell, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Laurell A, Lonnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017.